Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2017

View Archived Issues

FDA grants orphan drug designation to CK-101 for EGFR mutation-positive NSCLC

MP-0274 begins first-in-human study in HER2-positive solid tumors

New phase I trial evaluates CAR-20/19-T in patients with B-cell malignancies

ReLive trial of Livatag in HCC does not meet primary endpoint

Janssen discontinues further development of JNJ-4178

Primary endpoint not met in SPECTRI study of lampalizumab for geographic atrophy

Editas Medicine initiates clinical natural history study in patients with LCA10

HT-074 shows gastroprotection in experimental models of ulcer

ProQR spins out Amylon Therapeutics

Aldeyra Therapeutics reports results from phase IIa study of ADX-102 in dry eye disease

FDA grants priority review to sNDA for Trisenox

Two novel benzamides show promise for the treatment of schizophrenia

Phase III STATUS study of brexanolone does not meet primary endpoint

Abcellera Biologics, GSK form antibody discovery research collaboration

KemPharm submits amended NDA for Apadaz

NeuroDerm gives update on proposed acquisition by Mitsubishi Tanabe Pharma

Astellas seeks Japanese approval of Linzess for chronic constipation

Onxeo grants Monopar license for Validive

Targovax begins recruiting patients in phase I/II study of ONCOS-102 plus durvalumab

FDA awards fast track designation to SHP-607 to prevent lung disease in very premature infants

NIH announces awards to support development of 3-D human tissue models

Southwest Hospital patents LINC01094-siRNA2 for ischemic stroke

Inotek enters merger agreement with Rocket Pharmaceuticals

Novel mutation found for Niemann-Pick C1 disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...